MedTrace Logo

Empagliflozin in Treatment of Peripheral Diabetic Neuropathy

NCT05977465 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-11-24

No results posted yet for this study

Summary

The aim of the study is to investigate the possible protective effect of empagliflozin in patients with type 2 diabetes mellitus with diabetic peripheral neuropathy and not on SGLT2 inhibitors treatment.

Conditions

  • Diabetic Neuropathy Peripheral

Interventions

DRUG

Empagliflozin 25 MG

treatment

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Maha Khalifa, Pharm D · Tanta University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-20
Primary Completion
2023-08-01
Completion
2023-08-03

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05977465 on ClinicalTrials.gov